Abstract
Predicting the blood-brain barrier (BBB) permeability of small-molecule compounds is a critical bottleneck in central nervous system (CNS) drug discovery. This study presents a novel artificial intelligence platform that leverages the transformer-based Large Language Model (LLM) MegaMolBART and an XGBoost classifier to predict permeability from chemical structures. By treating Simplified Molecular Input Line Entry System (SMILES) strings as a chemical language, the model achieved an Area Under the Receiver Operating Characteristic (AUC) curve of 0.88 on a held-out test dataset. The computational results were validated in vitro using 3D human BBB spheroids and Liquid Chromatography-Tandem Mass Spectrometry (LC–MS/MS). The model correctly identified 21 permeable and 5 impermeable compounds, demonstrating that transformer-based architectures can significantly accelerate the identification of brain-penetrating therapeutics.
Introduction
The blood–brain barrier (BBB) is a highly selective semipermeable border that protects the brain from harmful substances while simultaneously blocking approximately 98% of potential small-molecule drugs. Traditional in silico prediction methods often rely on manual feature engineering of physicochemical properties, which can be computationally expensive and may fail to capture complex molecular geometries. This research explores a deep learning approach that bypasses manual descriptors by learning molecular representations directly from chemical "grammar."
Methods
In Silico Pipeline
The researchers utilized MegaMolBART, a transformer-based model pre-trained on millions of molecules from the ZINC-15 database. MegaMolBART serves as a SMILES encoder, generating high-dimensional embeddings that capture long-range dependencies within molecular structures. These embeddings were then used as inputs for an XGBoost classifier. To establish a baseline, the team compared this approach against traditional Morgan (Circular) fingerprints, which are the industry standard for molecular similarity.
In Vitro Validation
To confirm the accuracy of the AI predictions, the study employed 3D human BBB spheroids composed of human brain microvascular endothelial cells, brain vascular pericytes, and astrocytes. Compounds including Temozolomide (TMZ), Ferulic acid, and various natural products from the Natural Products Research Laboratories (NPRL) at China Medical University Hospital (CMUH) were tested. Permeability was verified using LC–MS/MS to detect the presence of compounds within the spheroid cells.
Results and Discussion
The integration of LLM embeddings with machine learning classifiers yielded superior results compared to traditional methods. The MegaMolBART variants (NGC and TWS embeddings) consistently outperformed Morgan fingerprints across multiple metrics, including AUC and Accuracy, particularly when tested on the specialized CMUH-NPRL dataset.
Analysis using t-SNE visualization revealed that natural products and general drug databases occupy distinct chemical spaces. The researchers found that training the model on a mixture of these datasets was vital for generalization. While the model showed high predictive power, it exhibited a tendency to overfit on smaller, specialized datasets, suggesting that future work should focus on expanding quantitative LogBB data to improve regression accuracy.
Experimental Validation
The biological validation phase provided strong evidence for the model's reliability. Temozolomide (TMZ), a known brain-penetrating drug, and NPRL309 were predicted as permeable (Pred score = 1) and showed clear peaks in the BBB cell mass spectrometry analysis. Conversely, Ferulic acid was predicted as impermeable and showed no significant penetration in the 3D spheroid model.
In total, the model achieved a 100% success rate in this validation subset, correctly identifying all 21 permeable and 5 impermeable compounds tested in vitro.
Conclusion
This study demonstrates that transformer-based models like MegaMolBART, which leverage the "language" of chemistry, offer a powerful and scalable alternative to traditional molecular modeling. By accurately predicting BBB permeability, these AI tools have the potential to reduce the time and cost associated with developing novel treatments for disorders such as Alzheimer’s, Parkinson’s, and brain tumors.
Summary updated